Abstract
Gynecologic cancer is a major burden in both developed and developing countries. Almost a half million deaths from gynecologic cancer are reported each year. Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets, which may be parlayed into novel therapeutic options in gynecologic cancer. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which plays a pivotal role in many aspects of malignant growth including cancer cell survival, migration, invasion, angiogenesis and metastasis. Various human cancer tissues have demonstrated high expression of FAK or activated FAK, which has been correlated with survival of cancer patients. Among gynecologic cancers, reports have emerged demonstrating that FAK is involved in the pathogenesis of ovarian, endometrial, and cervical cancers. In addition, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis. Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development.
Keywords: Focal adhesion kinase, EZH2, Dll4/notch, ovarian cancer, uterine cancer, cervix cancer, angiogenesis, endothelial cells, gynecologic cancer, polycomb group protein
Current Pharmaceutical Design
Title:Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Volume: 18 Issue: 19
Author(s): Duangmani Thanapprapasr, Wei Hu, Anil K Sood and Robert L Coleman
Affiliation:
Keywords: Focal adhesion kinase, EZH2, Dll4/notch, ovarian cancer, uterine cancer, cervix cancer, angiogenesis, endothelial cells, gynecologic cancer, polycomb group protein
Abstract: Gynecologic cancer is a major burden in both developed and developing countries. Almost a half million deaths from gynecologic cancer are reported each year. Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets, which may be parlayed into novel therapeutic options in gynecologic cancer. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which plays a pivotal role in many aspects of malignant growth including cancer cell survival, migration, invasion, angiogenesis and metastasis. Various human cancer tissues have demonstrated high expression of FAK or activated FAK, which has been correlated with survival of cancer patients. Among gynecologic cancers, reports have emerged demonstrating that FAK is involved in the pathogenesis of ovarian, endometrial, and cervical cancers. In addition, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis. Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development.
Export Options
About this article
Cite this article as:
Thanapprapasr Duangmani, Hu Wei, K Sood Anil and L Coleman Robert, Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer, Current Pharmaceutical Design 2012; 18 (19) . https://dx.doi.org/10.2174/138161212800626201
DOI https://dx.doi.org/10.2174/138161212800626201 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fucose Specific Lectins in Cancer Research and Diagnosis
Drug Design Reviews - Online (Discontinued) The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Anesthesia for Bronchoscopy
Current Pharmaceutical Design MEK Inhibitors: A Therapeutic Approach to Targeting the Ras-MAP Kinase Pathway in Tumors
Current Pharmaceutical Design Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction
Medicinal Chemistry Simultaneous Estimation of Artemisinin and Dexamethasone in Nanodispersions and Assessment of Ex-vivo Corneal Transport Study by RP- HPLC
Current Pharmaceutical Analysis Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design A Proteomics Study of the Subacute Toxicity of Rat Brain after Long- Term Exposure of <i>Gelsemium elegans</i>
Current Molecular Pharmacology Antineoplastic and Antimicrobial Potential of Novel Phytofabricated Silver Nanoparticles from <i>Pterospermum acerifolium</i> Leaf Extract
Nanoscience & Nanotechnology-Asia Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews Transendothelial Migration of Monocytes: The Underlying Molecular Mechanisms and Consequences of HIV-1 Infection
Current HIV Research Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Histopathology, Immunohistochemistry and Molecular Biology of Follicular Epithelium-Derived Pediatric Thyroid Carcinomas
Current Pediatric Reviews Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry